Search

Author/Creator Burger, Jan A

1. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Issue 10 (October 2020)

Authors:
DiNardo, Courtney D; Maiti, Abhishek; Rausch, Caitlin R; Pemmaraju, Naveen; Naqvi, Kiran; Daver, Naval G; Kadia, Tapan M; Borthakur, Gautam; Ohanian, Maro; Alvarado, Yesid; Issa, Ghayas C; Montalban-Bravo, Guillermo; Short, Nicholas J; Yilmaz, Musa; Bose, Prithviraj; Jabbour, Elias J; Takahashi, ...
Journal:
Lancet
Issue:
Volume 7:Issue 10(2020)
Page Start:
e724
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial. Issue 2 (February 2019)

Authors:
Nastoupil, Loretta J; Lunning, Matthew A; Vose, Julie M; Schreeder, Marshall T; Siddiqi, Tanya; Flowers, Christopher R; Cohen, Jonathon B; Burger, Jan A; Wierda, William G; O'Brien, Susan; Sportelli, Peter; Miskin, Hari P; Purdom, Michelle A; Weiss, Michael S; Fowler, Nathan H
Journal:
Lancet
Issue:
Volume 6:Issue 2(2019)
Page Start:
e100
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗